MannKind Presents New Data on Inhaled Insulin at ADA 2026 Meeting

MannKind Corporation announced new clinical and real-world data on its inhaled insulin product at the American Diabetes Association's 2026 Scientific Sessions, held June 5-8 in New Orleans, Louisiana. The presentations build on the FDA's May 29, 2026 approval of the product for children and adolescents aged 6 and older with type 1 or type 2 diabetes.

A post hoc analysis from the INHALE-1 study found that pediatric participants achieving HbA1c below 8 percent reported greater treatment satisfaction with inhaled insulin than with rapid-acting analogs. A subgroup analysis of youth with baseline HbA1c at or below 9.5 percent showed non-inferior HbA1c outcomes and comparable time in range after 26 weeks, with adverse event rates similar to adult data.

An interim analysis of meal-challenge data indicated that inhaled insulin produced comparable glucose control to rapid-acting analogs in gestational diabetes, with nominally fewer hypoglycemic events. An exploratory evaluation of inhaled insulin paired with automated insulin delivery systems suggested that glycemic outcomes may differ depending on whether algorithms rely on total daily dose.

Other presentations examined dosing strategies in adults with type 1 diabetes, Medicare Part D utilization after the insulin cost cap, and real-world lung cancer incidence among type 2 diabetes patients using inhaled insulin. A euglycemic clamp study showed that more than 50 percent of the inhaled insulin's pharmacodynamic effect occurred within 60 minutes, compared with 10 percent for insulin lispro.

"As we continue to advance care for people living with diabetes, and on the heels of the recent approval of Afrezza in children and adolescents aged 6 and older, the data presented at this year's ADA meeting further reinforce its established safety and efficacy," said Dr.

Kevin Kaiserman, Senior Vice President and Therapeutic Area Head-Diabetes for MannKind Corporation.